Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Xbrane Biopharma AB (publ) releases interim report for the period April - June 2016

Xbrane Biopharma AB
Posted on: 22 Aug 16

Press Release

Xbrane Biopharma ABs interim report for the period April-June 2016 is now available on the Company's website, .

Period April-June 2016

  • Group net sales amounted to 1 032 017 (75 000) SEK
  • Group total income amounted to 1 108 233 (85 512) SEK
  • Earnings before tax amounted to -7 556 986 (-1 333 280) SEK

Significant events during the period

  • Xbrane established a new state-of-the-art laboratory for biosimilar development in our new facilities in Solna.
  • Xbrane established an agreement with the Lithuanian contract manufacturer Biotechpharma to produce Xlucane in commercial scale under GMP conditions.
  • Xbrane conducted the technology transfer of Xlucane to our partner Helvetic Biopharma in Iran.

Significant events after the period

  • Xbrane submitted the application for GMP approval for our Spherotide production facility
  • Xbrane licensed out its protein expression technology to Oxford Nanopore Technologies for production of proteins used in their DNA sequence equipment

About Xbrane
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing generics for injectable controlled release drugs and proprietary high-yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company's portfolio of High Demand Complex Generics. Xbranes's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3 rd under the name XBRANE and Avanza Bank AB is Xbranes certified advisor. For more information see .

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777

This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 August 22 2016.

Press release - Q2 interim report
Q2 2016-Xbrane-English

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Xbrane Biopharma AB via GlobeNewswire

Last updated on: 23/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.